These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 19224847)

  • 1. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.
    Feldman DR; Baum MS; Ginsberg MS; Hassoun H; Flombaum CD; Velasco S; Fischer P; Ronnen E; Ishill N; Patil S; Motzer RJ
    J Clin Oncol; 2009 Mar; 27(9):1432-9. PubMed ID: 19224847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma.
    Molina AM; Feldman DR; Voss MH; Ginsberg MS; Baum MS; Brocks DR; Fischer PM; Trinos MJ; Patil S; Motzer RJ
    Cancer; 2012 Apr; 118(7):1868-76. PubMed ID: 21898375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Hudes GR; Ginsberg MS; Baum MS; Harmon CS; Kim ST; Chen I; Redman BG
    Am J Clin Oncol; 2010 Dec; 33(6):614-8. PubMed ID: 20142724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of sunitinib plus bevacizumab in advanced solid tumors.
    Rini BI; Garcia JA; Cooney MM; Elson P; Tyler A; Beatty K; Bokar J; Mekhail T; Bukowski RM; Budd GT; Triozzi P; Borden E; Ivy P; Chen HX; Dolwati A; Dreicer R
    Clin Cancer Res; 2009 Oct; 15(19):6277-83. PubMed ID: 19773375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma.
    Rini BI; Stein M; Shannon P; Eddy S; Tyler A; Stephenson JJ; Catlett L; Huang B; Healey D; Gordon M
    Cancer; 2011 Feb; 117(4):758-67. PubMed ID: 20922784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).
    Grünwald V; Desar IM; Haanen J; Fiedler W; Mouritzen U; Olsen MW; van Herpen CM
    Acta Oncol; 2011 Jan; 50(1):121-6. PubMed ID: 21174612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicity of sunitinib plus bevacizumab in renal cell carcinoma.
    Rini BI; Garcia JA; Cooney MM; Elson P; Tyler A; Beatty K; Bokar J; Ivy P; Chen HX; Dowlati A; Dreicer R
    J Clin Oncol; 2010 Jun; 28(17):e284-5; author reply e286-7. PubMed ID: 20439632
    [No Abstract]   [Full Text] [Related]  

  • 8. Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis.
    Ravasio R; Ortega C; Sabbatini R; Porta C
    Clin Drug Investig; 2011; 31(7):507-17. PubMed ID: 21627339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
    Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma.
    Rini B; Redman B; Garcia JA; Burris HA; Li S; Fandi A; Beck R; Jungnelius U; Infante JR
    Ann Oncol; 2014 Sep; 25(9):1794-1799. PubMed ID: 24914044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
    J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies.
    Bruce JY; Kolesar JM; Hammers H; Stein MN; Carmichael L; Eickhoff J; Johnston SA; Binger KA; Heideman JL; Perlman SB; Jeraj R; Liu G
    Cancer Chemother Pharmacol; 2014 Mar; 73(3):485-93. PubMed ID: 24414551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.
    Mickisch G; Gore M; Escudier B; Procopio G; Walzer S; Nuijten M
    Br J Cancer; 2010 Jan; 102(1):80-6. PubMed ID: 19920817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
    Thompson Coon J; Hoyle M; Green C; Liu Z; Welch K; Moxham T; Stein K
    Health Technol Assess; 2010 Jan; 14(2):1-184, iii-iv. PubMed ID: 20028613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness.
    Thompson Coon JS; Liu Z; Hoyle M; Rogers G; Green C; Moxham T; Welch K; Stein K
    Br J Cancer; 2009 Jul; 101(2):238-43. PubMed ID: 19568242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
    Motzer RJ; Tannir NM; McDermott DF; Arén Frontera O; Melichar B; Choueiri TK; Plimack ER; Barthélémy P; Porta C; George S; Powles T; Donskov F; Neiman V; Kollmannsberger CK; Salman P; Gurney H; Hawkins R; Ravaud A; Grimm MO; Bracarda S; Barrios CH; Tomita Y; Castellano D; Rini BI; Chen AC; Mekan S; McHenry MB; Wind-Rotolo M; Doan J; Sharma P; Hammers HJ; Escudier B;
    N Engl J Med; 2018 Apr; 378(14):1277-1290. PubMed ID: 29562145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study.
    Atkins MB; Gravis G; Drosik K; Demkow T; Tomczak P; Wong SS; Michaelson MD; Choueiri TK; Wu B; Navale L; Warner D; Ravaud A
    J Clin Oncol; 2015 Oct; 33(30):3431-8. PubMed ID: 26304872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors.
    Négrier S; Pérol D; Bahleda R; Hollebecque A; Chatelut E; Boyle H; Cassier P; Metzger S; Blanc E; Soria JC; Escudier B
    BMC Cancer; 2017 Aug; 17(1):547. PubMed ID: 28810837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial.
    Robert NJ; Saleh MN; Paul D; Generali D; Gressot L; Copur MS; Brufsky AM; Minton SE; Giguere JK; Smith JW; Richards PD; Gernhardt D; Huang X; Liau KF; Kern KA; Davis J
    Clin Breast Cancer; 2011 Apr; 11(2):82-92. PubMed ID: 21569994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma.
    Campbell MT; Millikan RE; Altinmakas E; Xiao L; Wen SJ; Siefker-Radtke AO; Aparicio A; Corn PG; Tannir NM
    Clin Genitourin Cancer; 2015 Jun; 13(3):218-24. PubMed ID: 25465491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.